The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series C | Dead

Total Raised


Last Raised


About Satori Pharmaceuticals

Satori Pharmaceuticals is a developing therapeutics for Alzheimer's Disease (AD). The company is developing small molecule compounds that are orally active and designed for chronic dosing in seniors. The highly selective gamma secretase modulators reduce the production of amyloid beta 42, while sparing other gamma substrates. This selectivity and expected safety profile provide the opportunity for Satori's lead compounds to treat patients in early-stage disease, potentially slowing or stopping the disease, before major brain damage or onset of clinical symptoms.

Satori Pharmaceuticals Headquarter Location

281 Albany Street

Cambridge, Massachusetts, 02139,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Satori Pharmaceuticals Patents

Satori Pharmaceuticals has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Alzheimer's disease, Transcription factors, Rare diseases, Proteins, Cognitive disorders


Application Date


Grant Date



Related Topics

Alzheimer's disease, Transcription factors, Rare diseases, Proteins, Cognitive disorders



Latest Satori Pharmaceuticals News

Concert, Alere, TremRx, & More Names from Boston Life Sciences News

Mar 2, 2012

XconomyBoston —  Acquisitions, licensing deals, and companies emerging from stealth mode made up the New England life sciences news this week. —My colleague Arlene took a closer look at the Alzheimer’s drugmaker Satori Pharmaceuticals, which last week scored a $15 million venture funding round . Cambridge, MA-based Satori is looking to an unusual source to develop Alzheimer’s drugs : the flowering herbaceous plant black cohosh, which is most commonly marketed as a nutritional supplement to relieve menopause symptoms such as hot flashes. —We reported on two big Boston-area acquisitions : Waltham, MA-based Alere’s $270 million-plus acquisition of the toxicology screening tech company eScreen, and Japan-based Dainippon Sumitomo Pharma’s acquisition of Boston Biomedical, a maker of drugs targeting cancer stem cells.

  • When was Satori Pharmaceuticals founded?

    Satori Pharmaceuticals was founded in 2004.

  • Where is Satori Pharmaceuticals's headquarters?

    Satori Pharmaceuticals's headquarters is located at 281 Albany Street, Cambridge.

  • What is Satori Pharmaceuticals's latest funding round?

    Satori Pharmaceuticals's latest funding round is Series C.

  • How much did Satori Pharmaceuticals raise?

    Satori Pharmaceuticals raised a total of $47.5M.

  • Who are the investors of Satori Pharmaceuticals?

    Investors of Satori Pharmaceuticals include New Enterprise Associates, InterWest Partners, Prospect Venture Partners, PureTech and Queensland BioCapital Funds.

  • Who are Satori Pharmaceuticals's competitors?

    Competitors of Satori Pharmaceuticals include Humanetics Corporation, Annovis Bio, Intarcia Therapeutics, Bellus Health, Synapsin Pharmaceuticals and 12 more.

You May Also Like

Humanetics Corporation

Humanetics Corporation is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs with a focus on radiation modulators for oncology, medical imaging and medical countermeasure uses.

NeoCytex BioPharma

NeoCytex BioPharmaceuticals develops therapeutics to promote the repair and rejuvenation of damaged tissues. The lead drug candidate NBI-18 is being developed for speeding up recovery from neurodegenerative (Parkinson's, Alzheimer's) and cerebrovascular diseases.


CEPTYR, Inc., was founded to focus on developing drugs against protein tyrosine phosphatases (PTPs), a largely unexplored domain in pharmaceutical development. The company's first disease targeted is diabetes and obesity.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.


Osteologix develops pharmaceutical products for bone and cartilage disorders addressing large markets and offering low-risk development. The therapies developed by Osteologix represent valuable solutions to the patients suffering from diseases of bone and cartilage, and they represent cost-effective therapeutic options for the healthcare providers. Osteologix's lead compound for prophylaxis and treatment of osteoporosis is being developed for multiple clinical indications. The main program is aimed at osteoporosis. Additional programs are aimed at secondary indications in metabolic bone diseases and OA exploiting maximal synergies with the Osteoporosis program.

Cosmo S.p.A.

Cosmo is a fully-integrated speciality pharmaceutical company that aims to become engaged in the market of optimised therapies for selected gastro-intestinal diseases. The company's clinical development pipeline specifically addresses treatments for Inflammatory Bowel Diseases (IBD), such as Ulcerative Colitis and Crohn's Disease, as well as for colon infections.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.